The pharmacokinetics of linezolid in the non-inflamed human eye

Br J Ophthalmol. 2005 Nov;89(11):1418-9. doi: 10.1136/bjo.2005.073700.

Abstract

Aim: This study describes the ocular pharmacokinetics of linezolid, an antibiotic with broad spectrum activity against those Gram positive bacteria that are the most frequent cause of postoperative endophthalmitis.

Method: Patients undergoing routine cataract surgery were given a single oral 600 mg dose of linezolid at a variable time before surgery. Aqueous and serum levels of linezolid were assayed by high performance liquid chromatography, and a pharmacokinetic curve constructed from the pooled results.

Results: Orally administered linezolid rapidly achieves levels in the aqueous of non-inflamed eyes that exceed the concentration required to kill Gram positive bacteria (maximum mean concentration 6.8 (SD 1.2) microg/ml at 2-4 hours post-dose). An effective concentration is maintained for at least 12 hours, the standard interdose interval for this antimicrobial.

Conclusion: Linezolid offers the possibility of a rapid, oral approach to effective treatment of most cases of postoperative endophthalmitis, with the potential of improving visual outcome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetamides / blood
  • Acetamides / pharmacokinetics*
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / blood
  • Anti-Bacterial Agents / pharmacokinetics*
  • Antibiotic Prophylaxis*
  • Aqueous Humor / metabolism*
  • Cataract Extraction*
  • Endophthalmitis / prevention & control
  • Female
  • Gram-Positive Bacterial Infections / prevention & control
  • Humans
  • Linezolid
  • Male
  • Middle Aged
  • Oxazolidinones / blood
  • Oxazolidinones / pharmacokinetics*

Substances

  • Acetamides
  • Anti-Bacterial Agents
  • Oxazolidinones
  • Linezolid